Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Ravi Amaravadi, MD
- Target Recruit Count
- 94
- Registration Number
- NCT04464759
- Locations
- 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States
Neoadjuvant Immunotherapy in Brain Metastases
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Sarah Sammons, MD
- Target Recruit Count
- 1
- Registration Number
- NCT04434560
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
- Conditions
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 1
- Registration Number
- NCT04429321
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT04416568
- Locations
- 🇺🇸
Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Bradley A. McGregor, MD
- Target Recruit Count
- 60
- Registration Number
- NCT04413123
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸UT Southwestern Medical, Dallas, Texas, United States
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 159
- Registration Number
- NCT04396860
- Locations
- 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸Logan Health Medical Center, Kalispell, Montana, United States
🇺🇸Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
- Conditions
- Castration-Resistant Prostate CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Prostate CarcinomaMetastatic Urothelial CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Aggressive Variant Prostate CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT04388852
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04361162
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT04340193
- Locations
- 🇺🇸
Local Institution - 0059, Louisville, Kentucky, United States
🇸🇬Local Institution - 0027, Singapore, Singapore
🇺🇸Local Institution - 0189, Coronado, California, United States
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04319224
- Locations
- 🇺🇸
The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Virginia Health Systems, Charlottesville, Virginia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.